Cargando…

Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features

The broadly neutralizing antibody (bnAb) VRC01 is being evaluated for its efficacy to prevent HIV-1 infection in the Antibody Mediated Prevention (AMP) trials. A secondary objective of AMP utilizes sieve analysis to investigate how VRC01 prevention efficacy (PE) varies with HIV-1 envelope (Env) amin...

Descripción completa

Detalles Bibliográficos
Autores principales: Magaret, Craig A., Benkeser, David C., Williamson, Brian D., Borate, Bhavesh R., Carpp, Lindsay N., Georgiev, Ivelin S., Setliff, Ian, Dingens, Adam S., Simon, Noah, Carone, Marco, Simpkins, Christopher, Montefiori, David, Alter, Galit, Yu, Wen-Han, Juraska, Michal, Edlefsen, Paul T., Karuna, Shelly, Mgodi, Nyaradzo M., Edugupanti, Srilatha, Gilbert, Peter B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459550/
https://www.ncbi.nlm.nih.gov/pubmed/30933973
http://dx.doi.org/10.1371/journal.pcbi.1006952
_version_ 1783410201457590272
author Magaret, Craig A.
Benkeser, David C.
Williamson, Brian D.
Borate, Bhavesh R.
Carpp, Lindsay N.
Georgiev, Ivelin S.
Setliff, Ian
Dingens, Adam S.
Simon, Noah
Carone, Marco
Simpkins, Christopher
Montefiori, David
Alter, Galit
Yu, Wen-Han
Juraska, Michal
Edlefsen, Paul T.
Karuna, Shelly
Mgodi, Nyaradzo M.
Edugupanti, Srilatha
Gilbert, Peter B.
author_facet Magaret, Craig A.
Benkeser, David C.
Williamson, Brian D.
Borate, Bhavesh R.
Carpp, Lindsay N.
Georgiev, Ivelin S.
Setliff, Ian
Dingens, Adam S.
Simon, Noah
Carone, Marco
Simpkins, Christopher
Montefiori, David
Alter, Galit
Yu, Wen-Han
Juraska, Michal
Edlefsen, Paul T.
Karuna, Shelly
Mgodi, Nyaradzo M.
Edugupanti, Srilatha
Gilbert, Peter B.
author_sort Magaret, Craig A.
collection PubMed
description The broadly neutralizing antibody (bnAb) VRC01 is being evaluated for its efficacy to prevent HIV-1 infection in the Antibody Mediated Prevention (AMP) trials. A secondary objective of AMP utilizes sieve analysis to investigate how VRC01 prevention efficacy (PE) varies with HIV-1 envelope (Env) amino acid (AA) sequence features. An exhaustive analysis that tests how PE depends on every AA feature with sufficient variation would have low statistical power. To design an adequately powered primary sieve analysis for AMP, we modeled VRC01 neutralization as a function of Env AA sequence features of 611 HIV-1 gp160 pseudoviruses from the CATNAP database, with objectives: (1) to develop models that best predict the neutralization readouts; and (2) to rank AA features by their predictive importance with classification and regression methods. The dataset was split in half, and machine learning algorithms were applied to each half, each analyzed separately using cross-validation and hold-out validation. We selected Super Learner, a nonparametric ensemble-based cross-validated learning method, for advancement to the primary sieve analysis. This method predicted the dichotomous resistance outcome of whether the IC(50) neutralization titer of VRC01 for a given Env pseudovirus is right-censored (indicating resistance) with an average validated AUC of 0.868 across the two hold-out datasets. Quantitative log IC(50) was predicted with an average validated R(2) of 0.355. Features predicting neutralization sensitivity or resistance included 26 surface-accessible residues in the VRC01 and CD4 binding footprints, the length of gp120, the length of Env, the number of cysteines in gp120, the number of cysteines in Env, and 4 potential N-linked glycosylation sites; the top features will be advanced to the primary sieve analysis. This modeling framework may also inform the study of VRC01 in the treatment of HIV-infected persons.
format Online
Article
Text
id pubmed-6459550
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-64595502019-05-03 Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features Magaret, Craig A. Benkeser, David C. Williamson, Brian D. Borate, Bhavesh R. Carpp, Lindsay N. Georgiev, Ivelin S. Setliff, Ian Dingens, Adam S. Simon, Noah Carone, Marco Simpkins, Christopher Montefiori, David Alter, Galit Yu, Wen-Han Juraska, Michal Edlefsen, Paul T. Karuna, Shelly Mgodi, Nyaradzo M. Edugupanti, Srilatha Gilbert, Peter B. PLoS Comput Biol Research Article The broadly neutralizing antibody (bnAb) VRC01 is being evaluated for its efficacy to prevent HIV-1 infection in the Antibody Mediated Prevention (AMP) trials. A secondary objective of AMP utilizes sieve analysis to investigate how VRC01 prevention efficacy (PE) varies with HIV-1 envelope (Env) amino acid (AA) sequence features. An exhaustive analysis that tests how PE depends on every AA feature with sufficient variation would have low statistical power. To design an adequately powered primary sieve analysis for AMP, we modeled VRC01 neutralization as a function of Env AA sequence features of 611 HIV-1 gp160 pseudoviruses from the CATNAP database, with objectives: (1) to develop models that best predict the neutralization readouts; and (2) to rank AA features by their predictive importance with classification and regression methods. The dataset was split in half, and machine learning algorithms were applied to each half, each analyzed separately using cross-validation and hold-out validation. We selected Super Learner, a nonparametric ensemble-based cross-validated learning method, for advancement to the primary sieve analysis. This method predicted the dichotomous resistance outcome of whether the IC(50) neutralization titer of VRC01 for a given Env pseudovirus is right-censored (indicating resistance) with an average validated AUC of 0.868 across the two hold-out datasets. Quantitative log IC(50) was predicted with an average validated R(2) of 0.355. Features predicting neutralization sensitivity or resistance included 26 surface-accessible residues in the VRC01 and CD4 binding footprints, the length of gp120, the length of Env, the number of cysteines in gp120, the number of cysteines in Env, and 4 potential N-linked glycosylation sites; the top features will be advanced to the primary sieve analysis. This modeling framework may also inform the study of VRC01 in the treatment of HIV-infected persons. Public Library of Science 2019-04-01 /pmc/articles/PMC6459550/ /pubmed/30933973 http://dx.doi.org/10.1371/journal.pcbi.1006952 Text en © 2019 Magaret et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Magaret, Craig A.
Benkeser, David C.
Williamson, Brian D.
Borate, Bhavesh R.
Carpp, Lindsay N.
Georgiev, Ivelin S.
Setliff, Ian
Dingens, Adam S.
Simon, Noah
Carone, Marco
Simpkins, Christopher
Montefiori, David
Alter, Galit
Yu, Wen-Han
Juraska, Michal
Edlefsen, Paul T.
Karuna, Shelly
Mgodi, Nyaradzo M.
Edugupanti, Srilatha
Gilbert, Peter B.
Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features
title Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features
title_full Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features
title_fullStr Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features
title_full_unstemmed Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features
title_short Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features
title_sort prediction of vrc01 neutralization sensitivity by hiv-1 gp160 sequence features
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459550/
https://www.ncbi.nlm.nih.gov/pubmed/30933973
http://dx.doi.org/10.1371/journal.pcbi.1006952
work_keys_str_mv AT magaretcraiga predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures
AT benkeserdavidc predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures
AT williamsonbriand predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures
AT boratebhaveshr predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures
AT carpplindsayn predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures
AT georgievivelins predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures
AT setliffian predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures
AT dingensadams predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures
AT simonnoah predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures
AT caronemarco predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures
AT simpkinschristopher predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures
AT montefioridavid predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures
AT altergalit predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures
AT yuwenhan predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures
AT juraskamichal predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures
AT edlefsenpault predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures
AT karunashelly predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures
AT mgodinyaradzom predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures
AT edugupantisrilatha predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures
AT gilbertpeterb predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures